Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) lost -2.91 Percent and closed its previous trading session at $4.01. The stock traded with the average Volume of 1.07 Million at the end of last session.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has the Market Capitalization of 318.55 Million. The Stock has its 52-week High of $4.51 and 52-Week Low of $1.01 and it touched its 52-week high on 12/01/17 and 52-Week Low on 12/30/16.
The company reported its last earnings Actual EPS of $-0.05/share. While, the analyst predicted that the company could provide an EPS of $-0.06/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 16.7 Percent.
Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 17.1% where SMA50 and SMA200 are 34.22% and 65.83% respectively.
The company shows its Return on Assets (ROA) value of -45.8%. The Return on Equity (ROE) value stands at -49.1%.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) currently has a Weekly Volatility of 8.57% percent while its Monthly Volatility is at 7.60% percent. While talking about Performance of the Stock, Catalyst Pharmaceuticals, Inc. currently has a Weekly performance of 1.01%, monthly performance percentage is 27.3 percent, Quarterly performance is 52.47 percent, 6 months performance shows a percent value of 73.59% and Yearly Performance is 248.7 percent.
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven’s patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven’s vigabatrin-related foreign patents or patents pending worldwide. The Company’s initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted Fast Track status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.